{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:22:27Z","timestamp":1793380947055,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K07014"],"award-info":[{"award-number":["18K07014"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Insulin-like growth factor-2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types, and its expression is often associated with poor prognosis. IGF2BP3 expression has not been fully settled in vascular lesions.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We evaluated the expression of IGF2BP3 in malignant (angiosarcoma and epithelioid hemangioendothelioma [EHE]) and benign (hemangioma, granulation tissue cappilaries, and pyogenic granuloma) vascular lesions using immunohistochemistry. IGF2BP3 expression was scored as negative (0% of endothelial\/neoplastic cells), equivocal (1\u201325%), or positive (&gt;\u200926%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Eight of 30 (26.7%) cases of angiosarcoma and two of five (40%) cases of epithelioid hemangioendothelioma were positive for IGF2BP3. In contrast, hemangiomas (10 cases) and granulation tissue capillaries (12 cases) were all negative for IGF2BP3, and some cases of pyogenic granuloma (six of 14 cases) was scored as equivocal. In angiosarcoma, IGF2BP3 expression was independent of age, gender, location, morphological pattern, prognosis, presence of metastatic foci, and PD-L1 expression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>IGF2BP3 is a useful marker to distinguish between malignant and benign vascular lesions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13000-020-00951-x","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T07:02:28Z","timestamp":1584946948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions"],"prefix":"10.1186","volume":"15","author":[{"given":"Misuzu","family":"Okabayshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki R.","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Oji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Mibayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Odani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"951_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2014.07.006","volume":"29","author":"M Lederer","year":"2014","unstructured":"Lederer M, Bley N, Schleifer C, H\u00fcttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 2014;29:3\u201312.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"951_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3727\/096504008786991639","volume":"17","author":"SI Do","year":"2008","unstructured":"Do SI, Kim YW, Park HR, Park YK. Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma. Oncol Res. 2008;17(6):269\u201372.","journal-title":"Oncol Res"},{"issue":"10","key":"951_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.humpath.2011.12.020","volume":"43","author":"K Cornejo","year":"2012","unstructured":"Cornejo K, Shi M, Jiang Z. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma. Hum Pathol. 2012;43(10):1567\u201372.","journal-title":"Hum Pathol"},{"issue":"3","key":"951_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.humpath.2013.10.010","volume":"45","author":"H Yamamoto","year":"2014","unstructured":"Yamamoto H, Arakaki K, Morimatsu K, Zaitsu Y, Fujita A, Kohashi K, Hirahashi M, Motoshita J, Oshiro Y, Oda Y. Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors. Hum Pathol. 2014;45(3):481\u20137.","journal-title":"Hum Pathol"},{"issue":"4","key":"951_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.prp.2016.02.006","volume":"212","author":"T Shooshtarizadeh","year":"2016","unstructured":"Shooshtarizadeh T, Nazeri A, Zare-Mirzaie A, Movahedinia S. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma. Pathol Res Pract. 2016;212(4):335\u20139.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"951_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1066896915603119","volume":"24","author":"G Bellezza","year":"2016","unstructured":"Bellezza G, Prosperi E, Del Sordo R, Colella R, Rulli A, Sidoni A. IMP3 is strongly expressed in malignant Phyllodes tumors of the breast: an Immunohistochemical study. Int J Surg Pathol. 2016;24(1):37\u201342.","journal-title":"Int J Surg Pathol"},{"key":"951_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.humpath.2016.04.007","volume":"55","author":"K Takizawa","year":"2016","unstructured":"Takizawa K, Yamamoto H, Taguchi K, Ohno S, Tokunaga E, Yamashita N, Kubo M, Nakamura M, Oda Y. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. Hum Pathol. 2016;55:30\u20138.","journal-title":"Hum Pathol"},{"issue":"1","key":"951_CR8","first-page":"3","volume":"39","author":"C Burdelski","year":"2018","unstructured":"Burdelski C, Jakani-Karimi N, Jacobsen F, M\u00f6ller-Koop C, Minner S, Simon R, Sauter G, Steurer S, Clauditz TS, Wilczak W. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2018;39(1):3\u201312.","journal-title":"Oncol Rep"},{"issue":"2","key":"951_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CCO.0000000000000427","volume":"30","author":"Y Ishida","year":"2018","unstructured":"Ishida Y, Otsuka A, Kabashima K. Cutaneous angiosarcoma: update on biology and latest treatment. Curr Opin Oncol. 2018;30(2):107\u201312.","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"951_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/jclinpath-2017-204601","volume":"70","author":"E Shustef","year":"2017","unstructured":"Shustef E, Kazlouskaya V, Prieto VG, Ivan D, Aung PP. Cutaneous angiosarcoma: a current update. J Clin Pathol. 2017;70(11):917\u201325.","journal-title":"J Clin Pathol"},{"issue":"6","key":"951_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ejso.2018.02.246","volume":"44","author":"K Oashi","year":"2018","unstructured":"Oashi K, Namikawa K, Tsutsumida A, Takahashi A, Itami J, Igaki H, Inaba K, Yamazaki N. Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face -a retrospective study of 38 untreated cases in the Japanese population. Eur J Surg Oncol. 2018;44(6):823\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"951_CR12","first-page":"2179","volume":"15","author":"K Harati","year":"2018","unstructured":"Harati K, Kolbenschlag J, Bohm J, Niggemann H, Joneidi-Jafari H, Stricker I, Lehnhardt M, Daigeler A. Long-term outcomes of patients with soft tissue sarcoma of the chest wall: analysis of the prognostic significance of microscopic margins. Oncol Lett. 2018;15(2):2179\u201387.","journal-title":"Oncol Lett"},{"issue":"1","key":"951_CR13","doi-asserted-by":"publisher","first-page":"e1253657","DOI":"10.1080\/2162402X.2016.1253657","volume":"6","author":"Y Honda","year":"2016","unstructured":"Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology. 2016;6(1):e1253657.","journal-title":"Oncoimmunology."},{"issue":"2","key":"951_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/JID.2015.376","volume":"136","author":"L Groesser","year":"2016","unstructured":"Groesser L, Peterhof E, Evert M, Landthaler M, Berneburg M, Hafner C. BRAF and RAS mutations in sporadic and secondary pyogenic granuloma. J Invest Dermatol. 2016;136(2):481\u20136.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"951_CR15","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.humpath.2009.05.003","volume":"40","author":"RL King","year":"2009","unstructured":"King RL, Pasha T, Roullet MR, Zhang PJ, Bagg A. IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol. 2009;40(12):1699\u2013705.","journal-title":"Hum Pathol"},{"issue":"4","key":"951_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bcmd.2011.02.005","volume":"46","author":"M Stoskus","year":"2011","unstructured":"Stoskus M, Gineikiene E, Valceckiene V, Valatkaite B, Pileckyte R, Griskevicius L. Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities. Blood Cells Mol Dis. 2011;46(4):321\u20136.","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"951_CR17","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/modpathol.2012.84","volume":"25","author":"EM Hartmann","year":"2012","unstructured":"Hartmann EM, Be\u00e0 S, Navarro A, Trapp V, Campo E, Ott G, Rosenwald A. Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression. Mod Pathol. 2012;25(9):1227\u201335.","journal-title":"Mod Pathol"},{"issue":"4","key":"951_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1172\/JCI80046","volume":"126","author":"JK Palanichamy","year":"2016","unstructured":"Palanichamy JK, Tran TM, Howard JM, Contreras JR, Fernando TR, Sterne-Weiler T, Katzman S, Toloue M, Yan W, Basso G, Pigazzi M, Sanford JR, Rao DS. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest. 2016;126(4):1495\u2013511.","journal-title":"J Clin Invest"},{"key":"951_CR19","doi-asserted-by":"publisher","first-page":"e1025","DOI":"10.1038\/cddis.2013.545","volume":"5","author":"W Li","year":"2014","unstructured":"Li W, Liu D, Chang W, Lu X, Wang YL, Wang H, Zhu C, Lin HY, Zhang Y, Zhou J, Wang H. Role of IGF2BP3 in trophoblast cell invasion and migration. Cell Death Dis. 2014;5:e1025.","journal-title":"Cell Death Dis"},{"issue":"4","key":"951_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/jid.2014.480","volume":"135","author":"YS Sheen","year":"2015","unstructured":"Sheen YS, Liao YH, Lin MH, Chu CY, Ho BY, Hsieh MC, Chen PC, Cha ST, Jeng YM, Chang CC, Chiu HC, Jee SH, Kuo ML, Chu CY. IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma. J Invest Dermatol. 2015;135(4):1065\u201373.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"951_CR21","first-page":"12621","volume":"8","author":"J Lan","year":"2015","unstructured":"Lan J, Huang B, Liu R, Ju X, Zhou Y, Jiang J, Liang W, Shen Y, Li F, Pang L. Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors. Int J Clin Exp Pathol. 2015;8(10):12621\u201333.","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-020-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-020-00951-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-020-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:17:26Z","timestamp":1616458646000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-020-00951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1186\/s13000-020-00951-x","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"27 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients signed the \u201cKyoto University Hospital Informed Consent Form for the Non-therapeutic Use of Histopathological Materials\u201d, and signed forms were uploaded into each electronic health record. Clinical data and samples were used with the approval of the Institutional Review Board of Kyoto University Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}